Holmes Biopharma, Inc.: $1.2 Million Dollar Contract Awarded
16 4월 2008 - 10:00PM
Marketwired
SCOTTSDALE, ARIZONA announces the recent signing of a $1.2
million dollar contract with a large East Asian pharmaceutical
company. The contract establishes Holmes Biopharma with another
major multinational pharmaceutical company, generating substantial
Phase I clinical trial revenue for the Omaha operation.
Furthermore, this contract is a significant revenue source for
Holmes Biopharma's Data Management Center in Toronto, Canada.
"A significant component of this contract is the revenue
generated by our new Data Management Center. We are just beginning
to realize the potential of this highly profitable component of the
clinical research business," stated John F. Metcalfe President,
CEO, Holmes Biopharma, Inc.
About Holmes:
Holmes Biopharma, Inc. and its majority owned subsidiary, Qualia
Clinical Service, Inc. is a contract research organization focused
on providing integrated and cost effective clinical development
services. Currently, clinics operate in Omaha, Nebraska, USA,
Toronto, Canada and Kiev, Ukraine, Eastern Europe. For more
information about the company please visit our website at
www.holmesbiopharma.com.
On behalf of the Board of Directors
John F. Metcalfe, President
Certain statements in this press release constitute "forward
looking statements" within the meaning of the United States
Securities Legislation. The Company's actual results could differ
from those in the forward-looking statements. Do not construe this
information as investment advice. This is not a solicitation to buy
or sell securities. This does not purport to be a complete analysis
of the Company. Investing in securities is speculative and carries
a high degree of risk. Past performance does not guarantee future
results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All
information contained in this press release should be independently
investigated. This press release contains forward-looking
statements. These remarks involve risks and uncertainties. Risks
are not limited to quarterly fluctuations in results or the
companies' management of growth and competition. Other risks are
detailed in the Company's SEC filings. Actual results may differ
materially from such information set forth herein.
Contacts: Holmes Biopharma, Inc. John F. Metcalfe President
1-800-778-4990 Email: ir@holmesbiopharma.com Website:
www.holmesbiopharma.com
Swiftsure (CE) (USOTC:HLMB)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Swiftsure (CE) (USOTC:HLMB)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
Swiftsure International Inc (CE) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Holmes Biopharma, Inc. News Articles